PAX2 and hepatocellular carcinoma: As shown by our results, PAX2 showed strong predictive efficacy for HCC, with its expression positively correlated with clinical stage, lymph node metastasis, and HCC-related serum markers (CA199, FucAFP, ALD-A, and AFu), and negatively correlated with tumor differentiation level.